Healthcare Providers and Services
Company Overview of N-of-One Therapeutics, Inc.
N-of-One Therapeutics, Inc. provides clinical analysis, curation, and interpretation of a tumor's molecular profile to providers, diagnostic companies, individual physicians, and cancer patients. The company’s solutions include treatment strategy roadmaps, clinical trial matching, and diagnostic strategy roadmaps. Its solutions and services pivot on matching patient-specific tumor molecular profiling data with knowledge on diagnostic technologies and therapeutic options to identify relevant clinical strategies for each patient's unique cancer. The company supports oncologists by delivering content and clinical insights for cancer treatment decisions and diagnostic approaches. N-of-One Therap...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One Therapeutics, Inc.
Chairman and Chief Executive Officer
Compensation as of Fiscal Year 2013.
N-of-One Therapeutics, Inc. Key Developments
Life Technologies Selects N-Of-One to Provide Valuable Employee Benefit: Molecular Diagnostics and Treatment Strategies for Cancer Care
Oct 16 13
N-of-One, Inc. announced that Life Technologies has selected N-of-One to provide a new type of benefit to its approximately 10,000 employees. For the first time, Life Technologies employees will have confidential access to cancer treatment strategies as an employee benefit, including review of the most advanced treatment options available. N-of-One develops comprehensive molecular diagnostic strategies for physicians and their patients, and based on the findings of the testing, prepares comprehensive treatment reports outlining the therapeutic options available to the patients and their oncologists. The financial terms of the agreement are not disclosed. Under the terms of the agreement, Life Technologies employees can apply confidentially to work directly with N-of-One. The N-of-One team will coordinate genomic profiling of the cancer, interpretation of the diagnostic results, and development of a comprehensive Treatment Strategy Roadmap(TM) within a few weeks - all at no cost to the employee. This interpretation and synthesis includes the latest knowledge on cancer treatment options, both approved and in clinical trials, all specifically targeted to each patient's genetic tumor profile.
N-of-One Therapeutics, Inc Interprets 4,000(th) Sequenced Tumor
Aug 26 13
N-of-One Therapeutics, Inc. announced that it has analyzed and interpreted its 4,000(th) cancer patient tumor, an industry milestone. The challenge of precision medicine is the clinical interpretation of the sequencing data, the millions of clinical research findings, and thousands of clinical trials into available therapeutic options that can be easily utilized by treating physicians. The company's clinical interpretation, performed across 347 different cancer subtypes, including solid tumors and hematologic malignancies, has shown clinically actionable results, including: In more than 70% of cases, N-of-One(R)'s clinical interpretation revealed that there are significant therapeutic options available beyond the current standard of care. In the hundreds of direct patient cases that N-of-One(R) has followed through treatment, approximately 35% of treating physicians made an immediate change to their therapeutic strategy after they received the N-of-One(R) clinical interpretation. Of this cohort, 25% were interested in pursuing a clinical trial. The interpretation of molecular data for this cohort has led to the identification of clinical trials in 96% of interested patients. The enrollment rates for the group interested in a clinical trial was approximately 38%, and was 9.5% out of the total population of patients they followed. These rates are well above the national average of 3%.
N-of-One Therapeutics, Inc. Partners with Fox Chase Cancer Center to Provide Molecular Interpretation and Treatment Strategy Analysis for Patients Receiving CancerCode-45(TM) DNA Sequencing
Feb 21 13
N-of-One Therapeutics, Inc. announced a partnership with Fox Chase Cancer Center in Philadelphia, to provide molecular interpretation and treatment strategy analysis for genome sequencing and testing provided to advanced stage cancer patients through the Cancer Genome Institute at Fox Chase. Financial terms of the agreement are not disclosed. Under the terms of the agreement, N-of-One will analyze the molecular profile and mutations identified through genome sequencing of each patient's cancer and deliver comprehensive treatment strategy profiles, including data on approved and investigational therapies to Fox Chase physicians who have ordered the CancerCode-45 sequencing for a patient. The treatment strategy profile interprets and informs the findings from the test.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 16, 2013